<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369159</url>
  </required_header>
  <id_info>
    <org_study_id>BCX1812-305</org_study_id>
    <nct_id>NCT02369159</nct_id>
  </id_info>
  <brief_title>Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza</brief_title>
  <official_title>A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of&#xD;
      IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of&#xD;
      pediatric subjects with acute uncomplicated influenza.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2015</start_date>
  <completion_date type="Actual">May 14, 2020</completion_date>
  <primary_completion_date type="Actual">October 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.</measure>
    <time_frame>14 days</time_frame>
    <description>Safety evaluation included assessment of Adverse Events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Exposure of IV Peramivir as Measured by the Drug Concentration Over 6 Hours Post-dose</measure>
    <time_frame>up to 6 hours post peramivir infusion</time_frame>
    <description>Up to 4 blood samples will be drawn, where possible: immediately following infusion and 30 to 60 mins, 1 to 3 hrs and 4 to 6 hrs post-infusions. AUC calculations were performed in Phoenix WinNonlin using the linear/log trapezoidal rule. AUC0-last was calculated between start of the infusion and the time of the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever</measure>
    <time_frame>14 days</time_frame>
    <description>Time for fever resolution based on subject diary record of temperature recorded twice daily. A subject had resolution of fever if he/she had oral temperature of &lt; 99.4°F or an axillary temperature of &lt; 98.4°F and no antipyretic medications were taken for ≥ 12 hours. The time to resolution of fever was estimated for each age group and overall using the Kaplan-Meier method with temperature and symptom relief medication information obtained from the Subject Diary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Influenza Symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Subjects or parents or caregivers were asked to provide an assessment of age-appropriate influenza symptoms on a 4-point severity scale (0,absent; 1, mild; 2, moderate; 3, severe) twice daily beginning before screening on Day 1 until symptoms resolved or until the last follow-up visit. Time to alleviation of symptoms was the number of hours from initiation of study drug until the start of the time period in which all age-appropriate symptoms of influenza were either absent or present at a level no greater than mild for at least 21.5 (24 - 10%) hours. Subjects who did not experience alleviation of symptoms were censored at the last observed symptom assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reduction in Viral Shedding</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of viral shedding in bilateral, mid-nasal swab specimens taken at baseline and then on Day 3, 7 and 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Influenza Virus Titer in Nasopharyngeal Samples in Response to Treatment.</measure>
    <time_frame>Change from baseline assessed on days 3, 7 and 14.</time_frame>
    <description>Change in influenza viral titers was defined as the time-weighted change from Baseline in log_10 tissue culture infective dose_50 (TCID50/mL) and was summarized for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influenza-Related Complications Assessment.</measure>
    <time_frame>14 days</time_frame>
    <description>The investigator performed a full physical exam at baseline. At each follow-up visit, study personnel evaluated the subject for the presence of clinical signs and symptoms of the following influenza-related complications: sinusitis, otitis media, bronchitis, and pneumonia requiring antibiotic use, diagnosed after initiation of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Peramivir (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.&#xD;
Subjects ≥12 years will receive a dose of 600 mg.&#xD;
Subjects &lt;12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).&#xD;
Subjects &lt; 6 months will receive a dose of 8 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.&#xD;
Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).&#xD;
Subjects &lt; 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peramivir</intervention_name>
    <arm_group_label>Peramivir (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <arm_group_label>Oseltamivir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs and symptoms consistent with acute influenza infection consisting of an&#xD;
             oral temperature ≥ 100°F (37.8°C) or rectal temperature ≥ 101.3ºF (≥ 38.5ºC) with at&#xD;
             least one respiratory symptom (cough or rhinitis) OR Positive influenza determined by&#xD;
             PCR or Rapid Antigen Test&#xD;
&#xD;
          2. Onset of symptoms no more than 72 hours before presentation for screening for subjects&#xD;
             &lt; 2 years old.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding females&#xD;
&#xD;
          2. Development of symptoms while hospitalized&#xD;
&#xD;
          3. Presence of a chronic disease or illness that may indicate increased risk for&#xD;
             influenza-related complications&#xD;
&#xD;
          4. Presence of immunocompromised status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Vanchiere, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief, Pediatric Infectious Diseases, Louisiana State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peramivir Investigative Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir investigative site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peramivir Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <results_first_submitted>February 5, 2021</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2021</results_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Peramivir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02369159/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02369159/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peramivir</title>
          <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
        </group>
        <group group_id="P2">
          <title>Oseltamivir</title>
          <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITTI Population</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>E-R Population</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="0">Milestone only applied to Peramivir group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITTI) population included all randomized subjects and was the primary population for analyses of demography and subject accountability.</population>
      <group_list>
        <group group_id="B1">
          <title>Peramivir</title>
          <description>Age-appropriate single dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
        </group>
        <group group_id="B2">
          <title>Oseltamivir</title>
          <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Mean age (SD) is reported for the overall ITT population and for each of the 4 age groups</population>
          <units>Age at time of randomisation - years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="5.07"/>
                    <measurement group_id="B2" value="9.9" spread="4.99"/>
                    <measurement group_id="B3" value="8.4" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 28 days to &lt; 2-year-old cohort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.47"/>
                    <measurement group_id="B2" value="1.0" spread="NA">Only 1 participant in group</measurement>
                    <measurement group_id="B3" value="1.3" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2 to &lt; 7-year-old cohort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="1.47"/>
                    <measurement group_id="B2" value="4.7" spread="1.60"/>
                    <measurement group_id="B3" value="4.8" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 7 to &lt; 13-year-old cohort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="1.75"/>
                    <measurement group_id="B2" value="9.7" spread="1.92"/>
                    <measurement group_id="B3" value="9.6" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 13 to &lt; 18-year-old cohort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="7"/>
                    <count group_id="B3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.7" spread="1.45"/>
                    <measurement group_id="B2" value="15.9" spread="1.50"/>
                    <measurement group_id="B3" value="15.7" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Influenza Viral Titer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="114"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.</title>
        <description>Safety evaluation included assessment of Adverse Events (AEs).</description>
        <time_frame>14 days</time_frame>
        <population>The Safety population included all randomized subjects who received ≥ 1 partial dose of peramivir or oseltamivir.</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir</title>
            <description>Age-appropriate single dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.</title>
          <description>Safety evaluation included assessment of Adverse Events (AEs).</description>
          <population>The Safety population included all randomized subjects who received ≥ 1 partial dose of peramivir or oseltamivir.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe or life-threatening Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event possibly, probably, or definitely related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event leading to discontinuation from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Exposure of IV Peramivir as Measured by the Drug Concentration Over 6 Hours Post-dose</title>
        <description>Up to 4 blood samples will be drawn, where possible: immediately following infusion and 30 to 60 mins, 1 to 3 hrs and 4 to 6 hrs post-infusions. AUC calculations were performed in Phoenix WinNonlin using the linear/log trapezoidal rule. AUC0-last was calculated between start of the infusion and the time of the last measurable concentration.</description>
        <time_frame>up to 6 hours post peramivir infusion</time_frame>
        <population>The Intent-to-Treat (ITTI) population included all randomized subjects. Of these 114 subjects, 106 had sufficient PK samples collected for inclusion in the peramivir PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects &lt;2 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Peramivir (≥ 2 - &lt; 7 Years)</title>
            <description>12 mg/kg (max. 600 mg) dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O3">
            <title>Peramivir (≥ 7 - &lt; 13 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg).</description>
          </group>
          <group group_id="O4">
            <title>Peramivir (≥ 13 - &lt; 18 Years)</title>
            <description>600 mg dose Peramivir, administered as a single short iv infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Exposure of IV Peramivir as Measured by the Drug Concentration Over 6 Hours Post-dose</title>
          <description>Up to 4 blood samples will be drawn, where possible: immediately following infusion and 30 to 60 mins, 1 to 3 hrs and 4 to 6 hrs post-infusions. AUC calculations were performed in Phoenix WinNonlin using the linear/log trapezoidal rule. AUC0-last was calculated between start of the infusion and the time of the last measurable concentration.</description>
          <population>The Intent-to-Treat (ITTI) population included all randomized subjects. Of these 114 subjects, 106 had sufficient PK samples collected for inclusion in the peramivir PK analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-last</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56200" spread="21430"/>
                    <measurement group_id="O2" value="71200" spread="31380"/>
                    <measurement group_id="O3" value="87000" spread="40750"/>
                    <measurement group_id="O4" value="72400" spread="19970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53300" spread="19100"/>
                    <measurement group_id="O2" value="68100" spread="27060"/>
                    <measurement group_id="O3" value="81400" spread="35090"/>
                    <measurement group_id="O4" value="68300" spread="19190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever</title>
        <description>Time for fever resolution based on subject diary record of temperature recorded twice daily. A subject had resolution of fever if he/she had oral temperature of &lt; 99.4°F or an axillary temperature of &lt; 98.4°F and no antipyretic medications were taken for ≥ 12 hours. The time to resolution of fever was estimated for each age group and overall using the Kaplan-Meier method with temperature and symptom relief medication information obtained from the Subject Diary data.</description>
        <time_frame>14 days</time_frame>
        <population>Intent to treat infected (ITTI) population. Subjects who did not have resolution of fever were censored at the time of their last non-missing post-baseline temperature assessment; this included 1 subject in the '≥ 28 days - &lt; 2 years' cohort treated with Peramivir. Seventeen subjects were excluded from summaries due to missing data or events resolving prior to initiation of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects &lt;2 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Peramivir (≥ 2 - &lt; 7 Years)</title>
            <description>12 mg/kg (max. 600 mg) dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O4">
            <title>Oseltamivir (≥ 2 - &lt; 7 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Peramivir (≥ 7 - &lt; 13 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg).</description>
          </group>
          <group group_id="O6">
            <title>Oseltamivir (≥ 7 - &lt; 13 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Peramivir (≥ 13 - &lt; 18 Years)</title>
            <description>600 mg dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O8">
            <title>Oseltamivir (≥ 13 - &lt; 18 Years)</title>
            <description>75mg dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever</title>
          <description>Time for fever resolution based on subject diary record of temperature recorded twice daily. A subject had resolution of fever if he/she had oral temperature of &lt; 99.4°F or an axillary temperature of &lt; 98.4°F and no antipyretic medications were taken for ≥ 12 hours. The time to resolution of fever was estimated for each age group and overall using the Kaplan-Meier method with temperature and symptom relief medication information obtained from the Subject Diary data.</description>
          <population>Intent to treat infected (ITTI) population. Subjects who did not have resolution of fever were censored at the time of their last non-missing post-baseline temperature assessment; this included 1 subject in the '≥ 28 days - &lt; 2 years' cohort treated with Peramivir. Seventeen subjects were excluded from summaries due to missing data or events resolving prior to initiation of study drug.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="6.55"/>
                    <measurement group_id="O2" value="61.8" spread="NA">Only one participant in group</measurement>
                    <measurement group_id="O3" value="58.8" spread="8.42"/>
                    <measurement group_id="O4" value="16.0" spread="2.38"/>
                    <measurement group_id="O5" value="36.3" spread="5.00"/>
                    <measurement group_id="O6" value="29.7" spread="7.82"/>
                    <measurement group_id="O7" value="51.3" spread="11.59"/>
                    <measurement group_id="O8" value="43.9" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Influenza Symptoms</title>
        <description>Subjects or parents or caregivers were asked to provide an assessment of age-appropriate influenza symptoms on a 4-point severity scale (0,absent; 1, mild; 2, moderate; 3, severe) twice daily beginning before screening on Day 1 until symptoms resolved or until the last follow-up visit. Time to alleviation of symptoms was the number of hours from initiation of study drug until the start of the time period in which all age-appropriate symptoms of influenza were either absent or present at a level no greater than mild for at least 21.5 (24 - 10%) hours. Subjects who did not experience alleviation of symptoms were censored at the last observed symptom assessment.</description>
        <time_frame>14 days</time_frame>
        <population>Intent to treat infected (ITTI) population. Subjects with no alleviation of symptoms were censored at date of last post-baseline assessment; including 1 subject in the '≥ 28 days to &lt; 2 yrs, Peramivir' group, 1 subject in the '≥ 2 to &lt; 7 yrs, Peramivir' group, 4 subjects in the '≥ 7 to &lt; 13 yrs, Peramivir' group and 1 subject each in the '≥ 13 to &lt; 18 yrs' Peramivir and Oseltamivir groups. Seven subjects were excluded due to missing data or events resolving prior to initiation of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects &lt;2 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Peramivir (≥ 2 - &lt; 7 Years)</title>
            <description>12 mg/kg (max. 600 mg) dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O4">
            <title>Oseltamivir (≥ 2 - &lt; 7 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Peramivir (≥ 7 - &lt; 13 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg).</description>
          </group>
          <group group_id="O6">
            <title>Oseltamivir (≥ 7 - &lt; 13 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Peramivir (≥ 13 - &lt; 18 Years)</title>
            <description>600 mg dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O8">
            <title>Oseltamivir (≥ 13 - &lt; 18 Years)</title>
            <description>75mg dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Influenza Symptoms</title>
          <description>Subjects or parents or caregivers were asked to provide an assessment of age-appropriate influenza symptoms on a 4-point severity scale (0,absent; 1, mild; 2, moderate; 3, severe) twice daily beginning before screening on Day 1 until symptoms resolved or until the last follow-up visit. Time to alleviation of symptoms was the number of hours from initiation of study drug until the start of the time period in which all age-appropriate symptoms of influenza were either absent or present at a level no greater than mild for at least 21.5 (24 - 10%) hours. Subjects who did not experience alleviation of symptoms were censored at the last observed symptom assessment.</description>
          <population>Intent to treat infected (ITTI) population. Subjects with no alleviation of symptoms were censored at date of last post-baseline assessment; including 1 subject in the '≥ 28 days to &lt; 2 yrs, Peramivir' group, 1 subject in the '≥ 2 to &lt; 7 yrs, Peramivir' group, 4 subjects in the '≥ 7 to &lt; 13 yrs, Peramivir' group and 1 subject each in the '≥ 13 to &lt; 18 yrs' Peramivir and Oseltamivir groups. Seven subjects were excluded due to missing data or events resolving prior to initiation of study drug.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="19.77"/>
                    <measurement group_id="O2" value="98.9" spread="NA">Only one participant in group</measurement>
                    <measurement group_id="O3" value="94.1" spread="11.53"/>
                    <measurement group_id="O4" value="20.7" spread="2.32"/>
                    <measurement group_id="O5" value="66.6" spread="7.83"/>
                    <measurement group_id="O6" value="134.4" spread="15.74"/>
                    <measurement group_id="O7" value="101.3" spread="18.46"/>
                    <measurement group_id="O8" value="75.5" spread="12.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reduction in Viral Shedding</title>
        <description>Assessment of viral shedding in bilateral, mid-nasal swab specimens taken at baseline and then on Day 3, 7 and 14.</description>
        <time_frame>14 days</time_frame>
        <population>Intent to treat infected (ITTI) population + ITT population with positive baseline influenza viral titers [&gt; 0.5 log10 TCID50/mL]; a total of 84 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects &lt;2 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir (≥ 28 Days - &lt; 2 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Peramivir (≥ 2 - &lt; 7 Years)</title>
            <description>12 mg/kg (max. 600 mg) dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O4">
            <title>Oseltamivir (≥ 2 - &lt; 7 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Peramivir (≥ 7 - &lt; 13 Years)</title>
            <description>Age-appropriate dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg).</description>
          </group>
          <group group_id="O6">
            <title>Oseltamivir (≥ 7 - &lt; 13 Years)</title>
            <description>Weight-based dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Peramivir (≥ 13 - &lt; 18 Years)</title>
            <description>600 mg dose Peramivir, administered as a single short iv infusion</description>
          </group>
          <group group_id="O8">
            <title>Oseltamivir (≥ 13 - &lt; 18 Years)</title>
            <description>75mg dose of Oseltamivir as a capsule or oral suspension BID for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reduction in Viral Shedding</title>
          <description>Assessment of viral shedding in bilateral, mid-nasal swab specimens taken at baseline and then on Day 3, 7 and 14.</description>
          <population>Intent to treat infected (ITTI) population + ITT population with positive baseline influenza viral titers [&gt; 0.5 log10 TCID50/mL]; a total of 84 subjects.</population>
          <units>participants with positive viral titer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Influenza Virus Titer in Nasopharyngeal Samples in Response to Treatment.</title>
        <description>Change in influenza viral titers was defined as the time-weighted change from Baseline in log_10 tissue culture infective dose_50 (TCID50/mL) and was summarized for each treatment group.</description>
        <time_frame>Change from baseline assessed on days 3, 7 and 14.</time_frame>
        <population>The Intent To Treat Infected (ITTI) population included all subjects who were enrolled, received study drug, and had confirmed influenza A and/or B by PCR. Thirteen subjects were excluded due to a negative or missing baseline titer.</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir</title>
            <description>Age-appropriate single dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Influenza Virus Titer in Nasopharyngeal Samples in Response to Treatment.</title>
          <description>Change in influenza viral titers was defined as the time-weighted change from Baseline in log_10 tissue culture infective dose_50 (TCID50/mL) and was summarized for each treatment group.</description>
          <population>The Intent To Treat Infected (ITTI) population included all subjects who were enrolled, received study drug, and had confirmed influenza A and/or B by PCR. Thirteen subjects were excluded due to a negative or missing baseline titer.</population>
          <units>influenza viral titer - log10 TCID50/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="0.75" upper_limit="6.50"/>
                    <measurement group_id="O2" value="4.50" lower_limit="1.50" upper_limit="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Change rom baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-6.00" upper_limit="2.50"/>
                    <measurement group_id="O2" value="-3.25" lower_limit="-5.00" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" lower_limit="-6.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="-4.00" lower_limit="-5.25" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 - Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" lower_limit="-6.00" upper_limit="-0.25"/>
                    <measurement group_id="O2" value="-4.00" lower_limit="-5.25" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Influenza-Related Complications Assessment.</title>
        <description>The investigator performed a full physical exam at baseline. At each follow-up visit, study personnel evaluated the subject for the presence of clinical signs and symptoms of the following influenza-related complications: sinusitis, otitis media, bronchitis, and pneumonia requiring antibiotic use, diagnosed after initiation of treatment.</description>
        <time_frame>14 days</time_frame>
        <population>Intent-to-treat infected (ITTI) population</population>
        <group_list>
          <group group_id="O1">
            <title>Peramivir</title>
            <description>Age-appropriate single dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
          </group>
        </group_list>
        <measure>
          <title>Influenza-Related Complications Assessment.</title>
          <description>The investigator performed a full physical exam at baseline. At each follow-up visit, study personnel evaluated the subject for the presence of clinical signs and symptoms of the following influenza-related complications: sinusitis, otitis media, bronchitis, and pneumonia requiring antibiotic use, diagnosed after initiation of treatment.</description>
          <population>Intent-to-treat infected (ITTI) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Otitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were recorded on Day 1, Day 3, Day 7 and Day 14/Early Withdraw visit.</time_frame>
      <desc>Adverse events were graded through use of the Division of Acquired Immune Deficiency Syndrome (DAIDS) Tables for Grading Adult and Pediatric Adverse Experiences. Influenza-related complications were not considered AEs unless they met the criteria for an SAE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peramivir</title>
          <description>Age-appropriate single dose Peramivir, administered as a single short iv infusion:&#xD;
Subjects ≥12 years - 600 mg. Subjects &lt;12 years - 12 mg/kg (max. 600 mg). Subjects &lt; 6 months - 8 mg/kg.</description>
        </group>
        <group group_id="E2">
          <title>Oseltamivir</title>
          <description>Age appropriate oral dose of Oseltamivir BID for 5 days:&#xD;
Subjects ≥ 13 years - 75mg dose as a capsule or oral suspension. Subjects &lt; 13 years - weight-based dose as a capsule or oral suspension.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane hyperaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site coldness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Elevated blood lactate dehydrogenase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Carbon dioxide decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>BioCryst Pharmaceuticals Inc</organization>
      <phone>+1 919-859-1302</phone>
      <email>clinicaltrials@biocryst.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

